下载掌阅APP，畅读海量书库
立即打开
The BioNTech/Pfizer vaccine may be less effective against Omicron than earlier strains of coronavirus while still offering a degree of protection, according to a South African study that offers an early if incomplete glimpse of how the jab will stand up to the new variant.
根据南非的一项研究，Biotech/辉瑞疫苗对 Omicron变种的效果可能不如早期的新冠病毒毒株，但仍能提供一定程度的保护。这项研究对该疫苗如何抵御新变种提供了早期、不完整的一瞥。
Researchers from the African Health Research Institute reported the loss of immune protection from the vaccine was “extensive but incomplete” in the first published study that pitted the jab against Omicron.
非洲卫生研究所的研究人员在首次研究该疫苗对抗Omicron变种效果的研究中报告称，该疫苗的免疫保护丧失“广泛但没有完全丧失”。
The researchers took 14 plasma samples from 12 participants that had been vaccinated with two doses of the BioNTech/Pfizer jab, and tested the ability of the plasma to neutralise Omicron. The laboratory experiments found Omicron infection resulted in a 41-fold reduction in virus-blocking antibodies compared with the original strain of the virus detected in Wuhan almost two years ago.
研究人员从12名接种了两剂BioNTech/辉瑞疫苗的参与者身上提取了14份血浆样本，并测试了血浆中和Omicron变种的能力。实验室实验发现，与近两年前在武汉发现的原始毒株相比，Omicron变种导致病毒阻断抗体减少41倍。